Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2009

View Archived Issues

Screening study shows reduced prostate cancer risk with finasteride across PSA levels

Novel series of hypoxia-activated compounds identified by Threshold Pharmaceuticals

Array BioPharma patent claims new tyrosine kinase inhibitors for cancer treatment

Schering-Plough patent discloses novel gamma-secretase modulators for the treatment of AD

New compounds for the treatment of hepatitis C claimed in Schering-Plough patents

New liver X receptor ligands under study at Organon for atherosclerosis

New myocardial imaging tracer shows safety and good biodistribution profile in phase I trial

Novel inhibitors of Abeta calcium channel activity confer neuroprotection in vitro

Alkermes advances proprietary pipeline

Avineuro commences phase I AVN-101 study for Alzheimer's disease

Cancer Therapy & Research Center and OncoVista collaborate on OVI-117

Somaxon provides update on NDA for Silenor for insomnia

GLYC-101 achieves accelerated wound closure based on interim analysis

Gen-Probe acquires Tepnel Life Sciences

BioWa licenses Potelligent Technology to sanofi-aventis

Cordex Pharma and BG Medicine collaborate on phase II trial of CDP-1050

Array BioPharma initiates clinical trial for ARRY-403 in type 2 diabetes

Amarin's MAA for AMR-101 in Huntington's disease accepted for review

IntelGenx and Cary file NDA for antidepressant, CPI-300

Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer

Allergy signs distribution agreement with Nycomed Canada for Pollinex Quattro

Relaxin shows promising results in phase II study in acute heart failure

Coartem receives FDA approval for malaria in the U.S.

DSMB recommends continuation of phase III Iluvien studies

KAI initiates third phase IIa KAI-1678 trial for neuropathic pain

Genentech voluntarily withdraws Raptiva from the U.S. market

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...